Helen Davis

Securus Monitoring touts high-tech supervision tools for modern reentry, but its parent company's controversial history casts a long shadow over its promises.

With a new $300M fund, the Detroit PE firm hires three principals to accelerate its 'Fix and Build' strategy in lower middle-market manufacturing.

With $65M in new funding and a new CEO, Duos is betting big on a $200M NVIDIA GPU deal to become a key player in the booming Edge AI infrastructure market.

A new deal brings Nanox's low-radiation, cost-effective Nanox.ARC to orthopedic clinics, aiming to reshape point-of-care diagnostics in the region.

With its SMA drug stalled by a factory inspection, Scholar Rock secures major financing and signals a clear path to a transformative market debut in 2026.

Consumer electronics leader AUKEY snags three prestigious iF DESIGN AWARDs, proving that superior design is no longer a luxury—it's the standard.

HR Acuity's integration into the Workday ecosystem signals a major shift toward proactive, data-driven employee relations management for modern enterprises.

From a viral sensation to a retail powerhouse, shapewear brand Popilush marks four years of innovation, award-winning design, and rapid expansion.

Ag Growth International brings back its 23-year former CFO to the board, signaling a major push for operational excellence amid financial pressures.

Fresh off a major clinical trial victory, Alumis Inc. heads to a key investor conference. What's next for its promising pipeline and soaring stock?

A new era in hearing arrives with Cochlear's Nexa System, the world's first upgradeable implant, tackling India's vast auditory health challenges.

SaaS growth expert Eric Shoemaker takes the helm at Keebo, aiming to scale its AI-powered platform amid soaring enterprise demand for cloud cost control.

The airline will pay a massive fine for historical price-fixing, concluding a landmark legal battle that has reshaped the air cargo industry.

Shareholder approval paves the way for cancer therapy innovator VERAXA to go public, aiming to accelerate its next-gen antibody-drug conjugate pipeline.

As Canada prepares for generic Semaglutide, U.S. patients look north for relief from soaring drug costs, navigating a complex web of savings and risks.

The biopharma firm beats 2025 guidance on strong specialty and generic sales, forecasting another year of growth fueled by new product launches.

Strategic Storage Trust VI's new Toronto facility isn't just more space—it's a calculated response to the city's housing crunch and demographic boom.

With three new industry titans, investment firm MPearlRock is doubling down on its operator-led model to navigate CPG disruption and scale the next big brands.

H+H International boosts core profit but a massive German restructuring leads to a huge net loss. A harsh winter further clouds the 2026 forecast.

With over 180 organizations onboard in months, Salesforce's new 'agentic AI' platform aims to end the ticketing era and challenge ServiceNow's reign.